Sunday, 29 March 2020

Biosensors to collaborate with Terumo in Japan

08 February 2013 | News | By BioSpectrum Bureau

The co-promotion agreement commences in April 2013

The co-promotion agreement commences in April 2013

Singapore: Biosensors International, a developer, manufacturer and marketer of innovative medical devices, is collaborating with Japanese company Terumo to promote the Nobori drug-eluting stent (DES) system at specific specialist cardiology centers in Japan.

Nobori incorporates two elements of Biosensors-developed technology: Biolimus A9 (BA9), an anti-restenotic drug developed specifically for use with stents; and a unique abluminal biodegradable polymer coating. Following an agreement with Terumo to manufacture, market and sell DES systems incorporating this technology in Japan, Terumo introduced Nobori there in May 2011.

Since this time, the DES market in Japan has become increasingly competitive. This new agreement will allow two sales forces (Terumo and Biosensors Japan) to jointly promote Nobori, highlighting its outstanding long-term efficacy and safety.

"We have established a strong partnership with Terumo over many years, and are delighted by this latest agreement, which further enhances our long-term strategic relationship," commented Mr Jeffrey B. Jump, president of Biosensors' Cardiovascular Business Unit. "Our two companies will continue to work closely together to strengthen our respective technologies and provide continued patient benefit in Japan."

The co-promotion agreement commences in April 2013, for an initial period of three years.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Are women in the industry getting the required recognition for their efforts?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls